

PHARMACY POLICY STATEMENT

Marketplace

| | |
|------------------|---------------------------------|
| DRUG NAME | Scenesse (afamelanotide) |
| BENEFIT TYPE | Medical |
| STATUS | Prior Authorization Required |

Scenesse, approved by the FDA in 2019, is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). It was the first drug approved for the treatment of EPP. Scenesse is a structural analog of alpha-melanocyte stimulating hormone (alpha-MSH). It increases production of photoprotective eumelanin (a type of melanin pigment) in the skin to help reduce sensitivity to light.

EPP, a subtype of a broader group of disorders known as porphyrias, is a rare inherited metabolic disorder caused by deficiency of the enzyme ferrochelatase (FECH) due to mutations in the *FECH* gene. FECH has a role in the biosynthesis of heme. Low levels of FECH cause excess protoporphyrin to accumulate in certain tissues, which leads to the characteristic symptoms of EPP. The major symptom is skin hypersensitivity to sunlight and some types of artificial light. Complications may include gallbladder dysfunction and liver damage. Less commonly, EPP can be caused by a mutation in the *ALAS2* gene. In these cases, it is referred to as X-linked protoporphyria (XLP).

Scenesse (afamelanotide) will be considered for coverage when the following criteria are met:

Erythropoietic Protoporphyria (EPP)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a dermatologist, hepatologist, gastroenterologist, or hematologist; AND
3. Member has a documented diagnosis of EPP confirmed with biochemical testing that shows elevated total erythrocyte protoporphyrin concentration > 3x ULN and majority (>50%) metal-free vs. zinc-bound; AND
4. Member exhibits characteristic symptoms of EPP phototoxicity (e.g., intolerance to light including pain, swelling, burning, itching, and redness of the skin during or after exposure to sunlight) which interferes with their quality of life (i.e., interference with work, activities of daily living, lifestyle choices, etc.); AND
5. Sun avoidance and use of protective measures (i.e., sunscreen, protective clothing, etc.) have been inadequate in controlling EPP phototoxic reactions; AND
6. Member does NOT have any of the following:
 - a) EPP with severe hepatic involvement
 - b) Untreated malignant or premalignant skin lesions.
7. **Dosage allowed/Quantity limit:** One 16 mg subcutaneous implant every 2 months (medical justification is required for requests beyond 3 implants a year for seasonal coverage).
QL: 1 implant per 60 days; 3 implants per year.

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must document improvement of signs and symptoms of disease: Increased tolerance to sunlight exposure and/or decreased phototoxic pain; AND
2. Member is receiving skin exams as recommended in the prescribing information.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Scenesse (afamelanotide) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

| DATE | ACTION/DESCRIPTION |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 06/17/2020 | New policy for Scenesse created. |
| 10/24/2022 | Updated/added references. Added GI, hepatology, hematology to specialists. Removed pain medications from criteria. Reworded renewal criteria and added skin exam. |
| 07/02/2024 | Updated references. Changed elevated “free protoporphyrin in peripheral erythrocytes” to “total erythrocyte protoporphyrin concentration > 3x ULN and majority (>50%) metal-free vs. zinc-bound.” Removed genetic testing option as it is not recommended in the absence of biochemical testing (Dickey 2023). |

References:

1. Scenesse [package insert]. Clinuvel, Inc.; 2023.
2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyrin. *N Engl J Med*. 2015;373(1):48-59. doi:10.1056/NEJMoa1411481
3. Wensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. *Expert Rev Clin Pharmacol*. 2021;14(2):151-160. doi:10.1080/17512433.2021.1879638
4. American Porphyria Foundation. Erythropoietic protoporphyria (EPP) and X-Linked Protoporphyrin (XLP), <https://porphyriafoundation.org/for-patients/types-of-porphyrin/epp-xlp/>
5. Balwani M. Erythropoietic Protoporphyrin and X-Linked Protoporphyrin: pathophysiology, genetics, clinical manifestations, and management. *Mol Genet Metab*. 2019;128(3):298-303. doi:10.1016/j.ymgme.2019.01.020
6. Ahmed jan N, Masood S. Erythropoietic Protoporphyrin. [Updated 2023 Feb 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563141/>
7. Leaf RK, Dickey AK. How I treat erythropoietic protoporphyria and X-linked protoporphyria. *Blood*. 2023;141(24):2921-2931. doi:10.1182/blood.2022018688
8. Dickey AK, Naik H, Keel SB, et al. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria. *J Am Acad Dermatol*. 2023;89(6):1227-1237. doi:10.1016/j.jaad.2022.08.036

Effective date: 01/01/2025

Revised date: 07/02/2024